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Medication compliance aids (MCAs) to support adherence lack evidence for cost-effectiveness yet a 2001 survey in England 
estimated 100,000 patients receiving an MCA whilst living in their home.  
 
Objective(s) 
To obtain a contemporary estimate of MCA provision by community pharmacies in England and describe factors 
influencing pharmacist decision-making regarding MCA initiation. 
 
Methods 
A stratified random sample of two community pharmacies per county (n=40) in England were surveyed by telephone and a 
more detailed postal survey sent to participants expressing an interest. Data were collected to determine magnitude of 
MCA provision and, professional and administrative factors influencing initiation were reported as percentage (95% 
confidence interval) respondents reporting a factor.  
 
Results 
An estimated 273,529 MCAs are filled by community pharmacies in England with a median (IQR) of 20(10, 50) MCAs per 
pharmacy per month provided for patients living in their home. Practitioners’ judgement of appropriateness for MCA 
initiation was reported by 51.3 ±11% as the primary factor influencing decision-making relative to 16.3 ±8% and 20 ±8.8% 
reporting patient’s and carer’s opinion respectively. Some form of assessment tool was reported by 13 ±7.3% respondents.  
 
Postal survey respondents (n=31) indicated that decision-making regarding MCA initiation was often or always affected by 
suitability of medication for dispensing in an MCA by 58% ±17% of respondents; 74.2% ±15.4% and 53.3% ±17.9% of 
respondents’ decision-making was never or rarely affected by the risk of adverse events and reduced patient autonomy 
arising from an MCA respectively. 
 
Conclusions 
Provision of MCAs by pharmacies in England has more than doubled in the past decade. Beyond considering the practicalities 
of whether an MCA is suitable for a patient, there is limited evidence of pharmacists considering patient choice or risk of 
adverse events arising from sudden increased adherence prior to initiation. 
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Adherence to prescribed medication directions is a complex health behaviour which requires the 
patient to have the opportunity to access their medication, capability to take it as prescribed and 
motivation to adhere to the prescribed directions.(1)  Non-adherence may therefore be intentional 
with patients not having the motivation to adhere and thus choosing to deviate from prescribed 
directions or unintentional due to practical barriers such as forgetfulness, confusion or difficulty 
swallowing.  Often, however, patients report an amalgam of both intentional and unintentional 
behaviour.(2)  It is unsurprising therefore that systematic reviews and meta-analyses of adherence 
interventions repeatedly conclude that the most effective interventions are complex in nature.(3)  
 
Historically, clinical practice has been dominated by simple adherence interventions such as 
provision of Multi-compartment Compliance Aids (MCAs) which are designed to support 
unintentional non-adherence.  MCAs are sometimes described as pill organisers and are generally 
variations on a box or blister pack with compartments divided into days of the week and times of the 
day in which medicines are organised according to their dose timings.  MCAs are intended to act as 
an aide memoire to prevent omission and duplication of doses.  Interviews with MCA users indicate 
that for those who self-fill their MCA, they help people to ‘bring order to chaos’ in terms of taking 
their medication regimen as prescribed.(4)  In contrast, interviews with older MCA users reported 
feelings of reduced autonomy arising from their medication being taken from its original packaging 
and dispensed into an MCA.  They also reported feeling that the MCA had been imposed on them in 
a paternalistic manner rather than as a shared decision.(5)  Questionnaire results from 96 frail older 
people who consented to participate in a North American trial of an electronic MCA reported that 
84% would consider using the MCA beyond the trial end.(6)  This positive attitude towards the MCA 
may be related to each trial participant actively choosing participation and therefore receipt of an 
MCA. 
A 2018 systematic review of factors affecting medication adherencesolely in the older population 
reported MCAs to be ineffective at improving adherence to the medication regimen.(7)  A 2011 
(8)and more recent 2016 (9) systematic review of MCAs including more heterogeneous populations 
have reported slightly more favourable findings for MCAs but both conclude that there is insufficient 
evidence to confirm that they are an effective and cost-effective adherence intervention.  Both 
systematic reviews conclude that further research is needed to improve the targeting of these 
devices to patients who are unintentionally non-adherent. 
Whilst evidence of universal benefit from MCAs is lacking, there is a substantial body of literature 
indicating that MCAs introduce greater risk of error associated with the dispensing and prescribing 
processes.  Dispensing into MCAs requires removal of medication from its original packaging.  This 
introduces potential hazards such as increased opportunity of dispensing errors and accidental 
ingestion by children as they are often not child resistant packaging.(10)  The integrity of the 
medication may also be compromised as MCAs do not always offer the level of protection afforded 
by the manufacturer’s original packaging.  A recent literature review of information sources utilised 
by pharmacists to determine medicine stability in an MCA outlined the need for pharmacists to 
access appropriate information sources to determine medication suitability for an MCA.  The review 
concluded that pharmacists should consider the physiochemical properties of the drug, the dosage 
form of the drug (e.g. some chewable tablets may be unsuitable for inclusion in an MCA), the co-
storage of drugs and the type of MCA including the levels of moisture permeation of the MCA 
material.(11)  Furthermore, an Australian study aimed to produce recommendations specific to 
repackaging medications into MCAs. Recommendations included counselling patients to store MCAs 




Additional patient confusion may also be generated by some medicines not being in the MCA such as 
those with hygroscopic properties or frequently changing doses being kept in original packaging.(13)  
A 2018 review of stability studies for repackaged medicines concluded that pharmacists should be 
mindful of these factors when initiating an MCA and provide counselling for patients regarding 
correct storage and usage.(11)  Repackaging medication into an MCA by members of the pharmacy 
team is estimated to take seven minutes for one patient with one month’s supply of only three 
medications.  This estimate excludes the time taken to unpack medication from its original packaging 
and labelling(14).  There is therefore a significant resource implication for community pharmacies 
filling MCAs.  Repackaging MCAs when regimes change partway through the MCA cycle generate 
further costs and pharmacy teams have described the challenges of managing these changes due to 
poor communication between the prescriber and pharmacy team.(15) 
Transfer of medication from original packaging to an MCA also restricts a patient’s ability to distinguish 
one medication from another.  In cases of intentional non-adherence, an MCA may lead patients to 
take none of their medication if they are unable to identify their chosen medication(s) to avoid.  
Conversely, in cases of purely unintentional non-adherence, a dramatic, sudden increase in adherence 
arising from MCA initiation may lead to dose related adverse effects.(16)  Furthermore, for the 
unintentionally non-adherent patient with impaired eyesight, manual dexterity or cognitive function, 
MCAs can present a greater challenge to the patient accessing their medication than the original 
manufacturer’s packaging. (17)  The extent to which alternative interventions to supporting adherence 
are being routinely used is unknown.  For example, increasing regimen complexity has been 
consistently associated with reduced adherence thus simplifying a regimen is an evidence-based 
approach to supporting unintentional non-adherence arising from mild confusion or forgetfulness.(18) 
A causal relationship has been identified between receipt of an MCA and provision of poorer quality 
medicines management.(19, 20)  Patients in receipt of an MCA were significantly more likely to be 
prescribed a potentially inappropriate medication relative to those without an MCA.(19)  The poorer 
medicines management was consistent even when patients were matched for age, sex and living 
status.  Suggested causes for this disparity included MCAs being associated with prescription 
renewal without review and reticence to make prescription amendments due to the added 
inconvenience of communicating changes to the pharmacy.(20)    
MCAs may be purchased by patients and self-filled or requested by other members of the healthcare 
team.  In the latter situation, MCAs are often provided and filled by a member of the pharmacy 
team.  Historically, many of these requests have been initiated by formal, paid carers to facilitate the 
medication administration process.  This has been described as an inappropriate use as it deskills 
carers.(21)  A 2001 evaluation of community pharmacies in one city in the North of England reported 
that 77% of the surveyed pharmacies filled one or more MCAs for use by patients in their own home.  
An average of 11 patients per pharmacy were reported to be provided with this service.  These data 
were extrapolated to estimate that over 100,000 patients living in their own home in Britain, receive 
an MCA filled by community pharmacy staff.(22)  A more recent 2015 survey of 48 pharmacies in 
one Scottish city, through extrapolation reported a greater than five-fold increase in MCA provision 
since 2001.(23)  There are however, no studies sampling pharmacies from more than one area in 
order to generate estimates regarding the number of patients receiving MCAs for use in their own 
home that are filled by community pharmacy teams.  The rationale for generating a contemporary 
estimate of the magnitude of this service provision is that there are additional costs incurred by 
community pharmacies, potential hazards to the MCA user and no agreed assessment criteria for 
MCA eligibility. 
Given that there is currently no standardised tool for assessing MCA appropriateness, it is anticipated 
that a variety of subjective factors are influencing the decision to initiate an MCA.  The present study 
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therefore aims to describe, at a national level, MCA provision from community pharmacies to patients 
living in their own home in terms of magnitude and factors influencing provision. 
 
Method: 
Ethical committee approval was obtained from the University of East Anglia Faculty of Medicine and 
Health Sciences research ethics committee for inviting staff of any community pharmacy in England 
registered to provide NHS services to complete a brief telephone survey regarding MCA provision and 
an optional supplementary survey inviting more detailed responses. 
 
Participant identification and recruitment 
A stratified, random sample, using a random number generator, of all 14,366 General Pharmaceutical 
Council registered pharmacies in England, was selected.  Stratification was by the 40 health regions in 
England approximating to the 48 counties.  Two pharmacies were randomly selected from each region 
in order to capture any variation in local policy and services that may influence MCA provision e.g. 
local arrangements for funding MCA provision by community pharmacies.  The sampling strategy 
yields a sample size of 80 pharmacies that is proportionate for the study aims.  Pharmacists, pharmacy 
technicians, dispensers and pharmacy managers were eligible.  Temporary pharmacists, hub 
pharmacies (pharmacies providing dispensing services on behalf of multiple community pharmacies) 
and pharmacies not providing MCAs were excluded. 
Each of the 80 selected community pharmacies were contacted by telephone and invited to 
participate in the survey.  A new pharmacy was randomly selected from the area if a pharmacy 
declined to participate or there was no answer after two attempts to contact by telephone. 
 
Following confirmation of not being a hub pharmacy, the brief survey was administered and 
participants invited to complete a further supplementary survey.  Those expressing a willingness to 
complete the supplementary survey were provided an electronic or postal version depending upon 
preference. 
 
Sample size estimation 
Based on the previous estimate of 77% of pharmacies providing MCA, a variety of sample sizes were 
investigated.(22)  A sample of one pharmacy per health region yielding a sample size of approximately 
40 would provide a 95% confidence interval of 13%.  Doubling to two pharmacies per region reduced 
the margin of error to within 9% for estimating the percentage of pharmacies providing MCAs and was 
therefore deemed acceptable. 
 
Survey development and content 
A 12 item survey informed by the MCA literature was developed to fulfil the study 
objectives.(5),(24)Face and content validity of the survey were investigated through cognitive 
interviews(25) with a convenience sample of community pharmacists identified from the 
professional network of the authors.  Cognitive interviewing allows evaluation of how the target 
audience perceives survey instruments and their constructs.  How a participant interprets a 
question, processes the information, applies information stored in memory and prepares a response 
are captured as verbal data during the cognitive interview process.  Data gathered may be used to 




The cognitive interview participants represented persons employed by independent pharmacies, 
small chains and large multiples.  Two community pharmacist interviews were undertaken before 
making any refinements to the survey.  Both pharmacists advised that all 12 items were valid but that 
the response burden was too great.  One interviewee additionally recommended that one of the items 
be split into two separate items.  This initial 12 item survey was subsequently split into a six-item 
survey administered by telephone with a further seven-item survey distributed by post to telephone 
respondents expressing an interest in ongoing study participation.  Further minor refinements were 
made to the surveys after a third interview; no recommendations for change were identified at the 
fourth interview thus this iteration of the surveys proceeded to the national survey. 
 
The brief six-item telephone survey was designed to quantify and describe MCA provision from 
community pharmacies to patients living in their own home.  Three items enabled characterisation of 
the survey respondent and a further three items were used to generate estimates for the following: 
1) magnitude of weekly MCA provision; 2) factors discouraging MCA initiation; 3) criteria for 
determining whether an MCA may be beneficial. 
 
In the seven item supplementary survey, a five point Likert scale ranging from “strongly disagree” to 
“strongly disagree” was used to ascertain the factors influencing choice of MCA from a pre-determined 
list of eight factors and option to add additional unlisted factors.  Further five point Likert scales 
ranging from rarely (1) to very frequently (5) were used to estimate frequency of the following during 
the previous year: 
1. The potential for negative outcomes (from a range of six outcomes) influencing decision 
making regarding MCA initiation 
2. Use of a range of nine adherence interventions other than MCAs 
3. Nature of communication between General Practitioner (GP) and pharmacist regarding MCAs 
in terms of four characteristics 
4. Requests to initiate MCAs from a range of seven different health and social care individuals  
An open question captured the information sources used to determine the physical stability of 
medications in an MCA and therefore inform the appropriateness of dispensing into an MCA.  Two 
further open questions captured respondents’ experiences of any requests for an MCA that were 
deemed inappropriate and any further comments. 
 
Analysis 
Descriptive statistics were calculated for all data collected and 95% confidence intervals reported for 
estimates regarding the key objectives of the brief survey.  To maintain anonymity, responses to the 
supplementary survey were not linked to the brief survey therefore, no inferential statistics were 
performed.  Data were entered into SPSS for windows version 22 for statistical analysis and content 
analysis was performed on extended responses provided in the supplementary survey. 
 
Results 
To obtain the 80 completed telephone surveys, 132 pharmacies were identified of which nine (6.8%) 
could not be contacted, one (0.8%) pharmacy used a hub pharmacy service and 38 (28.8%) refused to 
participate.  Four pharmacies (3.0%) did not provide MCAs to patients living in their home.  
From the 80 pharmacies providing MCAs and four pharmacies not providing MCAs, the estimated 
prevalence of pharmacies in England providing MCAs for patients living in their own home is therefore 
80/84 = 0.952 (95.2%, 95% confidence interval from 88% to 99%).  From the 80 respondents, the 
6 
 
median (IQ) number of MCAs dispensed per pharmacy per month was 20 (10, 50).  Based on 95.2% of 
14,366 pharmacies filling a median of 20 MCAs for patients living in their own home, the projected 
total number of MCAs supported by community pharmacies across England is 273,529. 
Of the 80 included pharmacies, 41 (51.3%) were independent and 39 (48.8%) were multiple.  The 
median (IQ) number of MCAs dispensed per multiple pharmacy, per month was 25 (10, 50) compared 
with 18 (10, 31.5) per month for independent pharmacies. Figure 1 illustrates the variations in the 
mean number of MCAs filled per month across health regions of the UK, ranging from 2 to 90. 
 
 





From the 80 respondents, 40 (50 %) were pharmacists, 22 (27.5%) were dispensing technicians or 
dispensers and 18 (22.5 %) were pharmacy managers with a median (IQR) duration in post of 6.5 years 
(2, 13.7).  Figure 1 illustrates the percentage (95% CI) around the respondents selecting one of five 
potential barriers to MCA initiation.  Lack of time and payment were the primary barriers, however, 
over a quarter of respondents perceived no factors discouraging initiation. 
 





Figure 3 provides the percentage (95% CI) of respondents selecting one of six factors as their primary 
influencer of decision making regarding whether a patient may benefit from an MCA.  Approximately 
50% of respondents selected either the opinion of the pharmacist or the GP as the single most 
important factor guiding decision-making.  In contrast, the two least favoured options were the 
patient’s opinion or results of a formal assessment.  For the ten respondents favouring a formal 
assessment, two each described them as a company standard operating procedure and local health 
service commissioner guidance whilst the remaining six respondents reported using the national 




Figure 3 Factors influencing decision marking regarding initiation of an MCA (n=80) 
Supplementary postal surveys were distributed to 58 pharmacies and 31 (53.4%) responses were 
obtained.  Table 1 provides the median and spread of responses to items inviting a Likert scale 
response from never (1) to very frequently (5).  The most frequent influencers of pharmacist opinion 
regarding whether to initiate an MCA were the suitability of the medications with 18 (58.1%) 
respondents indicating that it frequently or very frequently influenced their decision-making.  This was 
followed by the patient’s physical ability to use an MCA and ability to manage ‘when required’ 
medication which were both reported by 9 (29.1%) respondents as frequently or very frequently 
affecting the decision making.  The potential for an MCA to reduce patient autonomy, the risk of filling 
errors and risk of adverse events arising from a sudden increase in adherence due to the introduction 




Table 1: Responses to Supplementary Questionnaire. 
 
Question *Median (IQ) 
Frequency with which potential barrier to MCA initiation influenced decision making in the previous year 
Patient ability to use compliance aid 3 (2, 4) 
Adverse events if patient’s adherence is suddenly increased 2 (2, 3) 
Patient ability to manage ‘when required’ medication 3 (2, 4) 
Reducing patient autonomy 2 (2, 3) 
Some items being unsuitable for a compliance aid 4 (3, 4) 
Risk of error when filling 2 (1, 2) 
Frequency of using adherence interventions other than MCAs in the previous year 
Pictures and Symbols 2 (1, 2) 
Pill press or pill punch 2 (1, 3) 
Large print labels  3 (1, 3) 
Different languages/ interpreter 1.(1, 2) 
Simplification of regime 3 (2, 3) 
Medicines Administration Record (MAR) chart 3 (2, 4) 
Extra patient counselling 4 (3, 4) 
Prescription ordering 5 (4, 5) 
Referral for additional care support 3 (2, 3) 
Frequency of monitoring processes related to MCA provision in the previous year 
Communication to GP to inform that a compliance aid has been initiated 4 (3, 4) 
Communication from GP in a timely manner of prescription changes 4 (2, 4) 
Record of the brand of compliance aid provided 3 (1, 4) 
Review of patient’s need for and ability to use their compliance aid 3 (3, 4) 
Frequency with which the following sources request initiation of an MCA 
Social services carer 4 (3, 4) 
Relative/friend of patient 4 (3, 4) 
Hospital 3 (3, 4) 
District nurse 3 (2, 3) 
GP 4 (3,4) 
Patient 4 (3, 4) 
Yourself/other pharmacist 3 (3, 4) 
Frequency with which request is inappropriate 2 (1, 2) 
 
*Likert Scale responses from 1 to 5 where one indicates never and 5 indicates very frequently. 
 
The supplementary postal survey also captured the factors influencing choice of MCA.  The patient’s 
physical and cognitive ability were the key drivers of MCA choice, with 25 (80.7%) and 24 (77.4%) 
respectively, reporting that they agreed or strongly agreed that they influenced their decision-making.  
These practical factors were followed by patient preference for which 22 (70.9%) respondents agreed 
or strongly agreed.  The nature of the patient’s care arrangements e.g. whether they are living with 
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an informal carer influenced 21 (67.7%) respondents’ choice of MCA. The number and size of 
prescribed medication and ease of MCA transportability for the patient were statements to which 17 
(54.8%) and 11 (35.5%) respectively agreed or strongly agreed.  Company policy and the time taken to 
fill the MCA both received 8 (25.8%) respondents agreeing or strongly agreeing. 
Multiple resources were reportedly used to check the stability of medications in an MCA with some 
respondents reporting using several.  The most frequently cited resource was the product’s 
manufacturer either through direct contact, using the summary of product characteristics or the 
company website; this was reported by 10 (28.6%) respondents.  The national prescribing formulary 
was reported by 8 (22.9%) and product information leaflets by 6 (17.1%) of respondents as an 
information source.  The use of a medicines information service was reported by 7 (20.0%) 
respondents.  An article in a professional journal and materials produced by the UK Centre for 
Pharmacy Postgraduate Education were each reported by one respondent (5.7%).  Two (5.7%) of 
respondents reported referring to their pharmacist line manager for advice. 
From table 1, it can be seen that for patients known or suspected to be non-adherent, other than the 
use of an MCA, all respondents reported using pharmacy managed prescription ordering either 
frequently or very frequently during the previous year.  The use of extra patient counselling was also 
a frequently reported adherence intervention.  In contrast, simplification of medication regime and 
Medication Administration Records charts were reported to be used only sometimes or rarely by over 
80% of participants. 
No one process associated with monitoring patients using MCAs was consistently reported to be 
implemented frequently or very frequently.  Informing the GP of the initiation of an MCA was reported 
to occur very frequently by 22.6% of respondents.  Similarly, only 16.1% of respondents reported that 
communication from the GP about prescription changes was very frequently received in a timely 
manner and 25.8% reported that they were rarely received in a timely manner. 
Social services were the main source of requests to initiate an MCA with 58.1% of respondents 
reporting that this occurred frequently or very frequently during the previous year.  This was followed 
by the GP with 54.8% of respondents and patient with 48.4% of respondents reporting them to be 
frequently or very frequently requesting an MCA.  Ten (32.3%) respondents considered that during 
the past year they had received requests for an MCA that they considered inappropriate. 
Three themes were generated from the content analysis of responses to open questions and are 
provided in table 2.  Respondents described a variety of strategies to address the perceived insufficient 
resource currently available for MCA provision under the NHS contract.  These included direct 
remuneration for activities and managing capacity through requiring referral from a GP.  The second 
theme was the practical challenge of accommodating some MCA requests such as situations where 
there are frequent medication changes, daily dispensing is requested or medication stability may be 
compromised.  The third theme comprised situations where initiating an MCA was perceived 
inappropriate.  These were described either in terms of the patient’s physical or cognitive function 
being insufficiently impaired to warrant an MCA or being so impaired that they would be unable to 




Table 2: Categories arising from content analysis of extended responses 




resource for MCA 
provision 
“Pharmacies should be reimbursed for their time and cost involved in providing (buying) 
compliance aid. One solution is to provide weekly prescriptions to cover the cost.” 
“If we have numerous compliance aids to fill, we sometimes refer patients back to surgery to 
be signposted to a pharmacy that has more time or not so many patients, speaking to the 
patient first” 
“Because we are in a health centre most requests come from the GP. We also have some 
from the local medicine management group and they will clear the home of unwanted drugs 






“The patient must be physically able to receive the compliance aid upon delivery. They must 
be able to hear the door - this can prove challenging for the delivery driver” 






“Yes we had a couple of patients who requested a Dossett box weekly, but the pharmacist 
spoke to the Gp and he explained that the patients is young and can manage without it.” 
“I think patients should only [be] given compliance aids if they are old and they can’t look 
after themselves and…they need help with taking their medication. Patients who have 
physical ability or mental problem and not because are lazy to take their tablets. Aids are a 
life saver for patient [and] carer in the right context” 
“The request was made by a care company even though the patient was perfectly able to 
look after their own medication.” 
  
Requesting process 
for MCA initiation 
“Patient normally likes to have a compliance aid for medication but it has to be approved by 
GP as they need to issue weekly prescription for Dossett patients which involves a lot of time 
to get them ready for collection” 
“We often get asked by carers who work for agencies to issue compliance aids, quite often it 
is because carers are not permitted to issue medications to patients (as their company 
policy). We refer all requests for compliance aids to the patients GP’s who is better suited to 
assess the patient’s needs, so all out requests for compliance aids comes via the GP” 
“With CDS trays it’s a balance between the stability of the drugs and the patients taking 
them. Some patients are very confused and the trays are the only way for them to take their 
medicines on a regular basis…There has been quite a sudden decline in compliance aids as of 





“Most communication between primary and secondary care is in regards to changes, not 
initiation. There is little contact with social services and district nurses.” 





“Several patients with unstable medications liable to need dose adjustments constantly 
[and] patients prescribed 4 weeks at a time who are not capable of leaving the others aside 
end up taking random days from random blister packs rather than one at a time” 
“We had one request for compliance aid to be done daily (we usually do weekly boxes). 








This survey capturing any regional differences across the 40 counties in England estimates that over 
270,000 MCAs are filled by community pharmacies for patients living in their own home which is more 
than double the 2001 estimate.(22)  Insufficient time and remuneration for MCA provision were the 
most discouraging factors for initiation, however time was also the factor least influencing the choice 
of MCA.  Frequent requests for initiation by social services was consistently reported by respondents 
and the use of either the pharmacist’s or GP’s professional judgement for determining the 
appropriateness of initiation took precedence over the patient’s own opinion or the use of an 
assessment tool. 
Assessment of face and content validity of the survey using cognitive interviews enabled identification 
of flaws prior to the definitive study. Based on feedback during the cognitive interviews, the survey 
structure was amended in order to reduce the item burden. Previous qualitative work with 
pharmacists regarding the potential factors influencing MCA provision offered a strong grounding for 
development of the quantitative survey. .(5),(24)  The pre-testing phase with cognitive interviews 
provided further methodological rigour (25). Notable limitations of cognitive interviews are self-
selecting participants most commonly characterised by higher educational levels than average survey 
respondents. However, given the target population for the definitive study was qualified pharmacy 
professionals, this limitation is unlikely to have significant implications for the present study. 
Moreover, these motivated participants are unlikely to accurately capture motivational barriers to 
survey completion. However, the objective of the cognitive interviews in the present study was to 
assess face and content validity only, and the high survey completion rate in the main survey suggests 
motivation was not a barrier to completion. 
A survey response rate of nearly two thirds of the targeted pharmacies affords some confidence in 
the likely generalisability of the findings.  Furthermore, any regional variations in MCA supply and 
remuneration procedures have been captured by the purposive sampling.  Relative to the 2001 
evaluation of MCA provision in one UK city, the current national picture suggests that MCA supply is 
both more widespread and that the average number filled per pharmacy has also doubled. 
 
In England there have been no national policy changes to explain these increases which is endorsed 
by the main reported barriers to MCA supply still being a perception that there is insufficient 
workforce capacity and lack of proportionate remuneration for the service.(15, 22, 26)  Ageing 
increases the risks of some factors associated with unintentional non-adherence such as impaired 
manual dexterity, eye sight and cognitive function, thus the ageing population may provide some 
explanation for the increased estimate.(27)  Alternatively, greater precision in the estimate provided 
by the present national survey relative to the 2001 survey of one city may be responsible for the 
observed increase in MCA provision. 
 
Despite limited evidence supporting the use of MCAs,(9) few respondents were discouraged from 
initiation due to a perceived lack of efficacy.  With approximately one-third of community pharmacy 
staff perceiving no barrier to MCA use, this may reflect positive attitudes and experiences of MCAs, 
which accords with the existing literature.(28)  Given that insufficient time was a key barrier to MCA 
initiation, it may be expected that MCAs which require less time to fill are favoured.  Incongruously 
however, time taken to fill was the factor considered least likely to influence the choice of MCA.  
Similar to a previous review of pharmacy services across England for supporting adherence in the 
domiciliary setting,(29) extended survey responses indicated that there are regional variations in 
funding models for MCA filling by community pharmacies; some are formally remunerated for filling 
whilst others are reliant upon the funds within the community pharmacy contract for routine 
dispensing of prescriptions.  This may therefore generate inequity of access with some patients 
receiving the MCA filling service from their local community pharmacy whilst others are refused or 




The use of an assessment tool to inform the decision regarding MCA initiation was the least influential 
driver, which is unsurprising as there is no validated, widely accepted tool for assessing patient need 
for an MCA.  To reduce disparity in service provision there is clearly a need for such a tool, (15, 26, 28) 
however, limited research in this area is a key challenge to its development.  A cross-sectional study 
of 26 community pharmacy staff in Scotland reported that pharmacists did not feel confident in 
assessing patients’ needs for an MCA, nor whether they are capable of using it correctly.(24)  The 
pharmacists’ opinions taking precedence over the patient in determining the need for an MCA does 
therefore generate some concern, not only because pharmacists do not feel equipped to undertake 
this process, but also because patients should be central to decision making(30).  Given that older 
patients in receipt of MCAs have reported negative experiences associated with this paternalistic 
approach to MCA initiation,(5) practitioners should attempt to engage patients with the decision-
making. This devolvement of responsibility from patients to health practitioners may be a reflection 
of the population being considered for an MCA also being likely to have some level of cognitive 
impairment(31)  However, if the patient has the capacity to self-manage their medication using an 
MCA, they are likely to also have the capacity to engage with the decision making process regarding 
whether an MCA is acceptable and likely to be beneficial. (32)  
 
The criteria used to inform the pharmacist’s opinion regarding appropriateness of MCA initiation are 
focussed on the practicalities of whether the prescribed medications are suitable and whether the 
medication from the MCA can be accessed by the patient.  A similar picture is observed regarding the 
criteria informing the choice of MCA.  This absence of a patient focus may be appropriate given that a 
study of fifty older patients reported that patient preference for an MCA is dominated by its size rather 
than ability to access medication, with patients selecting the smallest MCA as most preferred 
regardless of their inability to access medication from the MCA.(17)   
 
The World Health Organisation patient safety challenge “Medication without harm” launched in 2017 
identifies that “health care professionals sometimes prescribe and administer medicines in ways and 
circumstances that increase the risk of harm to patients”.(33)  Inappropriate initiation of MCAs is one 
such example.  Prior to initiating any adherence intervention, a medication review to determine the 
appropriateness of prescribed medicines including dosage and formulation should be undertaken.(16)  
The rationale for this review is twofold. Firstly, dose titrations arising from perceived inadequate 
response to the medication can lead to doses not tolerated by the patient if they become suddenly 
adherent.  Secondly, between one to two thirds of older people are prescribed a potentially 
inappropriate medicine,(34) thus enforcing adherence before establishing whether all are appropriate 
may be introducing potential for further iatrogenic harm.  In contrast, pharmacy managed regular 
prescription ordering and medication counselling were the dominant adherence interventions. This 
may be due to pharmacies in the UK not having access to full medical records to facilitate medication 
review.  Moreover, the limited concern expressed by respondents regarding risk of a sudden 
improvement in adherence leading to dose related adverse events or the potential for MCAs to reduce 
patient autonomy despite evidence to the contrary may indicate a need for generating greater 
awareness of these risks. (35)   
 
The use of product manufacturers’ provided information being the preferred resource for checking 
medication stability may indicate a lack of awareness of the availability of open access databases for 
medication stability. This supports the conclusions of a recent review of medication stability which  
highlighted the need for an evidence-based source of stability and storage information for 
medications in MCAs.(11)  Improving sources of medication stability information could increase 
standardisation of MCA provision and reduce the risk of using unsuitable medications for MCAs. 
Repackaging error rates of 11.5% were reported in a large audit of MCAs in Australian care homes, 
with the majority of errors relating to medications being dispensed into MCAs which are unsuitable 
for repackaging.(36) Associated quality improvement strategies informed by focus groups with 
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healthcare professionals in Australia included improving the communication between prescribers, 
those dispensing MCAs and care home staff, and increasing knowledge and awareness of the 
guidelines for repackaging medicines into MCAs. 
 
The limited use of reminder charts is also surprising given that there is significant overlap between the 
functions of reminder charts and MCAs for patients where mild confusion and/or forgetfulness are 
the barriers to adherence.(37)  This may be indicative of MCAs being initiated before other lower 
intensity interventions have been tried.  Given that MCAs compared with lower intensity interventions 
are significantly more resource demanding for pharmacies to prepare and, are associated with 
reduced patient autonomy, research specifically capturing the interventions considered and/or tried 
before MCA initiation is required to enable a definitive conclusion to me made. 
The sporadic nature of communication between practitioners regarding MCA initiation and 
medication changes is of concern.  The limited communication emulates a 2005 survey investigating 
communication regarding MCA initiation from hospitals to community pharmacies with only 66 
(49.2%) reporting that this information is transferred to the community pharmacy.(26)  The present 
study adds to the existing literature through identifying similarly poor communication from GP 
surgeries to community pharmacies.  This was reported in the context of less than a quarter of 
pharmacies receiving information regarding medication changes from GPs.  Communication to the GP 
from the pharmacy regarding MCA initiation was marginally better.   
Consistent with the literature from a decade past, social services and GPs were the most frequent 
source of MCA requests and pharmacists the least likely.(22)  Notably, in the 2001 review of MCA 
provision patients were not cited as a source of MCA requests which contrasts the present findings 
and those reported from a recent Scottish survey.(24)  
The precision around the estimate of the prevalence of pharmacies in England providing MCAs 
should be interpreted in the context of a third of the targeted pharmacies not providing data 
regarding MCA provision.  However, given that 95% of the purposively sampled 80 pharmacies were 
comparable, it is unlikely that the true proportion differs significantly.  The data were generated 
from respondents self-reporting procedures relating to MCAs.  Whilst this may have resulted in 




Provision of MCAs in England for patients living in their own home has more than doubled in the past 
decade.  Beyond considering the practicalities of whether an MCA is suitable for a patient, there is 
limited evidence of appropriate safety checks prior to initiation.  There is therefore an urgent need to 
develop and validate an assessment tool to guide safe and appropriate MCA initiation. 
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